Abstract
420TiP UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have